BNR

Burning Rock Biotech Ltd (BNR) | Rumor.io

Burning Rock Biotech

BNR

Attention (50-day avg)0%

Attention rank (50-day avg)#3,733

Bullish sentiment (50-day avg)100%

Price to earnings ratio-3.45

Market capitalization185.9M

Earnings per share-0.84

Dividend yield (TTM)—

Revenue (annual)539.6M

Net income (annual)-55.3M

Social

What share of all stock conversation is about BNR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jan 6

Burning Rock Biotech Limited's ($BNR) stock price increased by 24.4%.
A research firm downgraded $BNR to Underweight with a price target of 50€, citing Chinese competition.
$BNR's potential for recovery has been negatively impacted by the competitive Chinese market.

Generated by AI

Sentiment

Of the messages about BNR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	97.44% +0.07
Bearish	—	—	0% 0	2.56% -0.07

Oct 5

Burning Rock Biotech Limited has a highly stacked professional team, indicating strong capabilities and potential for growth.
The company is showing strong work ethic, with its team working around the clock to drive progress and achieve success.
$BNR is expected to experience a significant bull run, with many analysts and investors predicting a sharp increase in value.

Generated by AI

Topics

Of the messages about BNR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	26.34%
Analysts	—	—	—	30.53%
Controversies	—	—	—	0%
Earnings	—	—	—	0.38%
Macro	—	—	—	30.92%
Technical Analysis	—	—	—	11.83%

Jan 3

Burning Rock Biotech Limited's OverC Multi-cancer Detection Blood test has received FDA Breakthrough Device Designation.
The stock price of BNR has experienced significant movement, with prices ranging from $2.10 to $2.87.
The FDA's Breakthrough Device Designation is expected to have a positive impact on the development and commercialization of Burning Rock's OverC test.

Generated by AI

Community

Of the messages about BNR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	5.26%	22.94%
Newcomers	—	—	94.74%	77.06%

Regulars· Nov 16

Burning Rock Biotech reported Q3 2022 financial results with a GAAP EPS of -$0.31, beating estimates by $0.03, and revenue of $21.74M, missing estimates by $0.32M.
The company's revenue of 8.42M RMB was reported in an earnings release on November 15, 21:20:00, with a delayed announcement.
Burning Rock Biotech's Q3 2022 financial results, including a GAAP EPS of -$0.31 and revenue of $21.74M, were presented in the company's earnings call presentation.

Newcomers· Oct 25

Newcomers to the BNR stock are focused on its potential to gain in the market, with some users mentioning it as one of the top gainers on Monday.
BNR is being considered as a top pot stock to keep an eye on in 2023, with some users including it in lists of stocks to watch.
Despite its inclusion in lists of top gainers and stocks to watch, BNR's actual performance and prospects are not being discussed in detail by these newcomers.

Generated by AI

News

Burning Rock Biotech Posts Q2 2026 Revenue Decline but Advances Fast-Track Reviews for Oncology NGS Kits

Detailed price information for Burning Rock Biotech Ltd ADR (BNR-Q) from The Globe and Mail including charting and trades.

19d agoThe Globe and Mail

Burning Rock Reports Second Quarter 2026 Financial Results

GUANGZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2026. Recent Business Updates Therapy Selection & MRD OncoScreen® BCMatch Tissue Kit has officially entered the Priority Review Channel of the Center for Medical Device Evaluation (

20d agoYahoo Finance

Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

1mo agoYahoo Finance

Also Discussed

Investors talking about BNR also mention

#	Name	Attention
1	Vanguard Mega Cap Value ETFMGV	0%0
2	CargoXCXO	0%0
3	CHN - The China Fund, Inc.	——
4	ProShares Ultra Health Care ETFRXL	0.01%+0
5	PNM Resources IncPNM	0%0
6	CDT Equity Inc.CDT	0%+0
7	Scully Royalty Ltd.SRL	0%new
8	Methode Electronics, Inc.MEI	0%0
9	Whitestone REITWSR	0%0
10	Sprinklr Inc Class ACXM	0%new

Burning Rock Biotech Ltd

Healthcare
Diagnostics & Research

Burning Rock Biotech Ltd. ADR is a China-based cancer diagnostics company focused on next-generation sequencing solutions for precision oncology. The company develops and commercializes cancer therapy selection tests designed to help physicians identify genetic alterations and match patients with targeted treatment options. Its business also includes cancer early detection services and pharma research and development support, giving it a role across both clinical care and biopharmaceutical research. Burning Rock Biotech serves hospitals, laboratories, and pharmaceutical partners in China and the United States, with operations centered on molecular diagnostics and liquid biopsy applications. Through its testing platforms and oncology-focused laboratory services, the company contributes to the broader adoption of genomics in cancer care and the use of data-driven diagnostics in modern medicine.

Website

Location

No. 5, Xingdao Ring Road North

Guangzhou, 510005

China

Social

What share of all stock conversation is about BNR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jan 6

Burning Rock Biotech Limited's ($BNR) stock price increased by 24.4%.
A research firm downgraded $BNR to Underweight with a price target of 50€, citing Chinese competition.
$BNR's potential for recovery has been negatively impacted by the competitive Chinese market.

Generated by AI

Sentiment

Of the messages about BNR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	97.44% +0.07
Bearish	—	—	0% 0	2.56% -0.07

Oct 5

Burning Rock Biotech Limited has a highly stacked professional team, indicating strong capabilities and potential for growth.
The company is showing strong work ethic, with its team working around the clock to drive progress and achieve success.
$BNR is expected to experience a significant bull run, with many analysts and investors predicting a sharp increase in value.

Generated by AI

Topics

Of the messages about BNR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	26.34%
Analysts	—	—	—	30.53%
Controversies	—	—	—	0%
Earnings	—	—	—	0.38%
Macro	—	—	—	30.92%
Technical Analysis	—	—	—	11.83%

Jan 3

Burning Rock Biotech Limited's OverC Multi-cancer Detection Blood test has received FDA Breakthrough Device Designation.
The stock price of BNR has experienced significant movement, with prices ranging from $2.10 to $2.87.
The FDA's Breakthrough Device Designation is expected to have a positive impact on the development and commercialization of Burning Rock's OverC test.

Generated by AI

Community

Of the messages about BNR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	5.26%	22.94%
Newcomers	—	—	94.74%	77.06%

Regulars· Nov 16

Burning Rock Biotech reported Q3 2022 financial results with a GAAP EPS of -$0.31, beating estimates by $0.03, and revenue of $21.74M, missing estimates by $0.32M.
The company's revenue of 8.42M RMB was reported in an earnings release on November 15, 21:20:00, with a delayed announcement.
Burning Rock Biotech's Q3 2022 financial results, including a GAAP EPS of -$0.31 and revenue of $21.74M, were presented in the company's earnings call presentation.

Newcomers· Oct 25

Newcomers to the BNR stock are focused on its potential to gain in the market, with some users mentioning it as one of the top gainers on Monday.
BNR is being considered as a top pot stock to keep an eye on in 2023, with some users including it in lists of stocks to watch.
Despite its inclusion in lists of top gainers and stocks to watch, BNR's actual performance and prospects are not being discussed in detail by these newcomers.

Generated by AI

Burning Rock Biotech

Social

Jan 6

Oct 5

Jan 3

Regulars· Nov 16

Newcomers· Oct 25

Burning Rock Biotech Posts Q2 2026 Revenue Decline but Advances Fast-Track Reviews for Oncology NGS Kits

Burning Rock Reports Second Quarter 2026 Financial Results

Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

Also Discussed

Burning Rock Biotech Ltd

Company Information

Location

Burning Rock Biotech Posts Q2 2026 Revenue Decline but Advances Fast-Track Reviews for Oncology NGS Kits

Burning Rock Reports Second Quarter 2026 Financial Results

Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

Also Discussed

Social

Jan 6

Oct 5

Jan 3

Regulars· Nov 16

Newcomers· Oct 25